Currently available in vitro assays have contributed to drug candidates targeting cardiac fibrosis, such as TGF-β inhibitors, renin–angiotensin–aldosterone system (RAAS) inhibitors, endothelin inhibitors, MMP inhibitors, relaxin, and others (reviewed in Fang et al., 2017). Here, REN is linked to fibrosis.